Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (25)
Xuezhen Zhou, Xi Lin, Runnan Shen, Yingying Qu, Chunling Mo, Yan Li, Qinchang Chen, Guitao Wu, Zhenhong Chen & Kai Huang. (2020) A retrospective analysis of risk factors associated with catheter-related thrombosis: a single-center study. Perfusion 35:8, pages 806-813.
Crossref
Crossref
Lisa A de Jong, Annette W G van der Velden, Marinus van Hulst & Maarten J Postma. (2020) Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. BMJ Open 10:11, pages e039057.
Crossref
Crossref
Ewa Zabrocka & Ewa Sierko. (2020) Thromboprophylaxis in the End-of-Life Cancer Care: The Update. Cancers 12:3, pages 600.
Crossref
Crossref
Devinder S. Dhindsa & Anant Mandawat. 2020. Handbook of Inpatient Cardiology. Handbook of Inpatient Cardiology
373
385
.
Alok A. Khorana, Keith R. McCrae, Dejan Milentijevic, Jonathan Fortier, Winnie W. Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre & Jeff Schein. (2019) Duration of anticoagulant therapy and VTE recurrence in patients with cancer. Supportive Care in Cancer 27:10, pages 3833-3840.
Crossref
Crossref
Jie Zeng, Xuhui Zhang, Gregory Y. H. Lip, Xiaochen Shu, Lehana Thabane, Junzhang Tian & Guowei Li. (2019) Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis 25, pages 107602961985362.
Crossref
Crossref
Wilbert S. Aronow & Tatyana A. Shamliyan. (2018) Oral Anticoagulation for Primary Prophylaxis of Venous Thromboembolism in Patients with Cancer. The American Journal of Medicine 131:8, pages 902-907.
Crossref
Crossref
Michael B. Streiff, Dejan Milentijevic, Keith McCrae, Daniel Yannicelli, Jonathan Fortier, Winnie W. Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Jeff Schein & Alok A. Khorana. (2018) Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. American Journal of Hematology 93:5, pages 664-671.
Crossref
Crossref
Simon Noble. (2018) Are new anticoagulants a safe and reasonable alternative to low molecular heparins?. Thrombosis Research 164, pages S157-S161.
Crossref
Crossref
I Ye Chazova, S A Tyulyandin, M V Vitsenia, E P Panchenko, Yu A Fedotkina, M G Poltavskaya, M Yu Gilyarov, T V Martynyuk, A G Ovchinnikov, M B Stenina, O P Trophimova & F T Ageev. (2018) Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Parts VI-VII. Systemic Hypertension 15:1, pages 6-20.
Crossref
Crossref
. 2018. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
145
201
.
Fenling Fan, Yuliang Zou, Songlin Zhang, Yushun Zhang, Beidi Lan, Qiang Song, Meili Pei, Lu He, Huili Wu, Yajuan Du & Anthony M. Dart. (2017) Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis. Clinical Therapeutics 39:9, pages 1882-1888.
Crossref
Crossref
Alok A. Khorana, Keith R. McCrae, Dejan Milentijevic, Jonathan Fortier, Winnie W. Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Daniel Yannicelli & Jeff Schein. (2017) Current practice patterns and patient persistence with anticoagulant treatments for cancer‐associated thrombosis. Research and Practice in Thrombosis and Haemostasis 1:1, pages 14-22.
Crossref
Crossref
I. Elalamy, I. Mahé, W. Ageno & G. Meyer. (2017) Long‐term treatment of cancer‐associated thrombosis: the choice of the optimal anticoagulant. Journal of Thrombosis and Haemostasis 15:5, pages 848-857.
Crossref
Crossref
José Miguel Rivera-Caravaca, Inmaculada Viedma-Viedma & Vanessa Roldán. (2016) Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. Biological Research For Nursing 19:2, pages 198-205.
Crossref
Crossref
Natale Daniele Brunetti, Enrico Gesuete, Luisa De Gennaro, Michele Correale, Pasquale Caldarola, Antonio Gaglione & Matteo Di Biase. (2017) Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. International Journal of Cardiology 230, pages 214-221.
Crossref
Crossref
Jonathan Kessler. 2017. Surgical Emergencies in the Cancer Patient. Surgical Emergencies in the Cancer Patient
79
91
.
Jose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Muñoz, Victor Aboyans, Riccardo Asteggiano, Maurizio Galderisi, Gilbert Habib, Daniel J. Lenihan, Gregory Y. H. Lip, Alexander R. Lyon, Teresa Lopez Fernandez, Dania Mohty, Massimo F. Piepoli, Juan Tamargo, Adam Torbicki, Thomas M. Suter, Jose Luis Zamorano, Victor Aboyans, Stephan Achenbach, Stefan Agewall, Lina Badimon, Gonzalo Barón‐Esquivias, Helmut Baumgartner, Jeroen J. Bax, Héctor Bueno, Scipione Carerj, Veronica Dean, Çetin Erol, Donna Fitzsimons, Oliver Gaemperli, Paulus Kirchhof, Philippe Kolh, Patrizio Lancellotti, Gregory Y. H. Lip, Petros Nihoyannopoulos, Massimo F. Piepoli, Piotr Ponikowski, Marco Roffi, Adam Torbicki, António Vaz Carneiro, Stephan Windecker, Stephan Achenbach, Giorgio Minotti, Stefan Agewall, Lina Badimon, Héctor Bueno, Daniela Cardinale, Scipione Carerj, Giuseppe Curigliano, Evandro de Azambuja, Susan Dent, Cetin Erol, Michael S. Ewer, Dimitrios Farmakis, Rainer Fietkau, Donna Fitzsimons, Oliver Gaemperli, Paulus Kirchhof, Philippe Kohl, Paul McGale, Piotr Ponikowski, Juergen Ringwald, Marco Roffi, Jeanette Schulz‐Menger, Justin Stebbing, Rudolf K. Steiner, Sebastian Szmit, Antonio Vaz Carneiro & Stephan Windecker. (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure 19:1, pages 9-42.
Crossref
Crossref
Winston Bonetti Yoshida. (2016) Anticoagulantes orais diretos no tratamento do tromboembolismo venoso em pacientes com câncer. Jornal Vascular Brasileiro 15:4, pages 263-264.
Crossref
Crossref
Simon I R Noble. (2016) Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins. The Lancet Haematology 3:8, pages e357-e358.
Crossref
Crossref
Harry E. Fuentes, Alfonso J. Tafur & Joseph A. Caprini. (2016) Cancer-associated thrombosis. Disease-a-Month 62:5, pages 121-158.
Crossref
Crossref
Abigail L Cohen, Chung S Lim & Alun H Davies. (2015) Is there a role yet for new direct oral anticoagulants in cancer patients?. Phlebology: The Journal of Venous Disease 31:3, pages 157-159.
Crossref
Crossref
Simon Noble & Jessica Sui. (2016) The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?. Thrombosis Research 140, pages S154-S159.
Crossref
Crossref
Aurélie Rousseau, Patrick Van Dreden, Elisabeth Mbemba, Ismail Elalamy, Annette Larsen & Grigoris T. Gerotziafas. (2015) Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. Thrombosis Research 136:6, pages 1273-1279.
Crossref
Crossref
H. Schinzel. (2018) Heparins – DOACS – VKA. Phlebologie 44:06, pages 307-315.
Crossref
Crossref